Athira Pharma (NASDAQ:LONA) Announces Quarterly Earnings Results

Athira Pharma (NASDAQ:LONA – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.27), Zacks reports.

Athira Pharma Trading Down 6.9%

Shares of Athira Pharma stock traded down $0.24 during mid-day trading on Monday, reaching $3.23. 58,400 shares of the stock were exchanged, compared to its average volume of 94,635. Athira Pharma has a fifty-two week low of $2.21 and a fifty-two week high of $14.21. The company has a market cap of $30.34 million, a price-to-earnings ratio of -0.77 and a beta of 1.90. The firm has a 50-day simple moving average of $5.34 and a 200 day simple moving average of $7.53.

Analysts Set New Price Targets

LONA has been the topic of a number of recent research reports. Wall Street Zen raised Athira Pharma to a “hold” rating in a research report on Saturday, October 17th. Mizuho cut their price target on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, August 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, November 4th. Finally, Citizens Jmp reduced their price objective on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research report on Monday, August 17th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

View Our Latest Analysis on LONA

Athira Pharma Company Profile

(Get Free Report)

Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair. The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis.

Read More

Earnings History for Athira Pharma (NASDAQ:LONA)

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.